DE69130113D1 - Proteine mit geänderten epitopen und verfahren zur deren herstellung - Google Patents

Proteine mit geänderten epitopen und verfahren zur deren herstellung

Info

Publication number
DE69130113D1
DE69130113D1 DE69130113T DE69130113T DE69130113D1 DE 69130113 D1 DE69130113 D1 DE 69130113D1 DE 69130113 T DE69130113 T DE 69130113T DE 69130113 T DE69130113 T DE 69130113T DE 69130113 D1 DE69130113 D1 DE 69130113D1
Authority
DE
Germany
Prior art keywords
epitopes
proteins
changed
production
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69130113T
Other languages
English (en)
Other versions
DE69130113T2 (de
Inventor
Uffe Loevborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130113(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69130113D1 publication Critical patent/DE69130113D1/de
Application granted granted Critical
Publication of DE69130113T2 publication Critical patent/DE69130113T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38645—Preparations containing enzymes, e.g. protease or amylase containing cellulase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38654—Preparations containing enzymes, e.g. protease or amylase containing oxidase or reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
DE69130113T 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung Revoked DE69130113T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90610072 1990-12-05
PCT/DK1991/000382 WO1992010755A1 (en) 1990-12-05 1991-12-05 Proteins with changed epitopes and methods for the production thereof

Publications (2)

Publication Number Publication Date
DE69130113D1 true DE69130113D1 (de) 1998-10-08
DE69130113T2 DE69130113T2 (de) 1999-05-12

Family

ID=8205875

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130113T Revoked DE69130113T2 (de) 1990-12-05 1991-12-05 Proteine mit geänderten epitopen und verfahren zur deren herstellung

Country Status (11)

Country Link
EP (1) EP0561907B1 (de)
JP (3) JP3355186B2 (de)
KR (1) KR100237968B1 (de)
AT (1) ATE170630T1 (de)
AU (1) AU9052891A (de)
BR (1) BR9107206A (de)
CA (2) CA2331936C (de)
DE (1) DE69130113T2 (de)
DK (1) DK0561907T3 (de)
FI (1) FI932561A0 (de)
WO (1) WO1992010755A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376061T1 (de) * 1992-07-17 2007-11-15 Genencor Int Hochalkalische serinproteasen
EP0786085A4 (de) * 1994-10-14 1999-02-03 Chiron Mimotopes Pty Ltd Verfahren und vorrichtung zur effizienten mimotop-erkennung
WO1998035026A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
KR20010034697A (ko) 1998-03-26 2001-04-25 데이비드 엠 모이어 아미노산 치환을 갖는 세린 프로테아제 변이체
KR20010052223A (ko) * 1998-03-26 2001-06-25 데이비드 엠 모이어 아미노산 결실 및 치환을 갖는 세린 프로테아제 변이체
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6461849B1 (en) * 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
EP1277762B1 (de) 1998-10-30 2008-03-26 Novozymes A/S Niedrigallergene Proteinvarianten
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
EP1051432B1 (de) * 1998-12-08 2007-01-24 Biovation Limited Verfahren zur verminderung der immunogenität von proteinen
AU777550B2 (en) * 1999-07-22 2004-10-21 Procter & Gamble Company, The Protease conjugates having sterically protected epitope regions
CN1399677A (zh) 1999-07-22 2003-02-26 宝洁公司 在确定表位区有氨基酸取代的枯草杆菌蛋白酶变体
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
AU5928200A (en) * 1999-07-22 2001-02-13 Procter & Gamble Company, The Intramolecularly cross-linked subtilisin proteases having reduced immunogenicity
KR20020021395A (ko) 1999-07-22 2002-03-20 데이비드 엠 모이어 입체적으로 보호된 ｃｌｉｐ 부위를 갖는 프로테아제콘쥬게이트
CN1373802A (zh) 1999-07-22 2002-10-09 宝洁公司 在特定表位区域具有氨基酸缺失和取代的枯草杆菌蛋白酶变体
US7226770B2 (en) * 2000-04-28 2007-06-05 Novozymes A/S Lipolytic enzyme variant
DZ3349A1 (fr) 2000-07-28 2002-02-07 Henkel Kgaa Nouvelle enzyme amylolytique issue de bacillus sp. a 7-7 (dsm 12368) ainsi que produits de lavage et nettoyage contenant ledit enzyme amylolytique
DE60144399D1 (de) * 2000-10-02 2011-05-19 Danisco Us Inc Methode zur bestimmung der immunogenität von proteinen, die eine veränderte immunantwort hervorrufen
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DK1373296T3 (da) * 2001-03-23 2012-01-09 Procter & Gamble Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
HUP0402334A3 (en) * 2001-09-04 2007-03-28 Merck Patent Gmbh Modified human growth hormone
BR0215383A (pt) * 2001-12-31 2006-11-28 Genencor Int proteases que produzem resposta imunogênica alterada e métodos de fabricação e uso das mesmas
BR0215415A (pt) * 2001-12-31 2005-04-05 Genencor Int Proteases produzindo uma resposta imunológica alterada e métodos de preparar e usar as mesmas
EP2295553A1 (de) 2002-02-08 2011-03-16 Novozymes A/S Phytasenvarianten
AU2003223934A1 (en) * 2002-05-16 2003-12-02 Alk Abello A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
JP4694966B2 (ja) 2002-07-30 2011-06-08 ジェネンコー・インターナショナル・インク エアロゾル生成を低減する製剤
AU2003276846A1 (en) * 2002-08-09 2004-02-25 Xencor Thrombopoiesis-stimulating proteins having reduced immunogenicity
ATE494368T1 (de) 2002-10-01 2011-01-15 Novozymes As Polypeptide der gh-61-familie
EP2500423B1 (de) 2003-02-26 2015-06-17 Danisco US Inc. Amylasen, die eine veränderte immunogene Reaktion bewirken, und Verfahren zu ihrer Herstellung und Verwendung
EP1597363B1 (de) 2003-02-26 2015-07-15 Danisco US Inc. Amylasen, die eine veränderte immunogene reaktion bewirken, und verfahren zu ihrer herstellung und verwendung
DK1639106T3 (da) 2003-06-19 2010-09-27 Novozymes As Proteaser
US20060236414A1 (en) 2003-06-19 2006-10-19 Novozymes A/S Proteases and methods for producing them
EP2308966A1 (de) 2003-10-10 2011-04-13 Novozymes A/S Proteasen
CA2542239C (en) 2003-10-16 2014-12-30 Micromet Ag Multispecific deimmunized cd3-binders
WO2005066339A2 (en) 2004-01-06 2005-07-21 Novozymes A/S Polypeptides of alicyclobacillus sp.
DE602005016773D1 (de) 2004-01-22 2009-11-05 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
CN103820423A (zh) 2004-04-02 2014-05-28 诺维信公司 具有改变的免疫原性的枯草杆菌酶变体
MXPA06014649A (es) 2004-06-21 2007-03-12 Novozymes As Proteasas.
AR050895A1 (es) 2004-10-04 2006-11-29 Novozymes As Polipeptidos que tienen actividad de fitasa y polinucleotidos que los codifican
EP2272964A3 (de) 2004-10-04 2011-08-31 Novozymes A/S Polypeptide mit Phytaseaktivität und dafür codierende Polynukleotide
WO2007019859A2 (en) 2005-08-16 2007-02-22 Novozymes A/S Polypeptides of strain bacillus sp. p203
EP3770174A1 (de) 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Zusammensetzungen mit antikörpern mit artenübergreifender spezifität und verwendungen davon
WO2007067473A2 (en) 2005-12-06 2007-06-14 Genencor International, Inc. Perhydrolase epitopes
EP2527370A1 (de) 2005-12-21 2012-11-28 Amgen Research (Munich) GmbH Verbindungen mit Resistenz gegen lösliche CEA
EP2270050B1 (de) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-C19 Antikörper mit reduzierter Immunogenizität
WO2007076933A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Interleukin-12p40 variants with improved stability
EP1998793A1 (de) 2006-03-22 2008-12-10 Novozymes A/S Verwendung von polypeptiden mit antimikrobieller wirkung
ES2387203T3 (es) 2006-04-04 2012-09-17 Novozymes A/S Variantes de fitasa
EP2455461B1 (de) 2006-12-21 2016-03-16 Novozymes A/S Lipasevarianten zur pharmazeutischen Verwendung
US8221743B2 (en) 2006-12-22 2012-07-17 Novozymes A/S Use of polypeptides against diseases caused by protozoans
EP2129781B1 (de) 2007-03-26 2014-01-22 Novozymes A/S Hafnia-phytase
US8206962B2 (en) 2008-09-26 2012-06-26 Novozymes A/S Hafnia phytase variants
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20170269092A1 (en) 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
WO2022034211A1 (en) 2020-08-13 2022-02-17 Novozymes A/S Phytase variants and polynucleotides encoding same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903068A (en) * 1972-12-26 1975-09-02 Us Health Education & Welfare Facile synthesis of human insulin by modification of porcine insulin
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
DK316989D0 (da) * 1989-06-26 1989-06-26 Novo Nordisk As Enzymer

Also Published As

Publication number Publication date
JP2002101880A (ja) 2002-04-09
JPH06502994A (ja) 1994-04-07
CA2331936A1 (en) 1992-06-06
CA2095852C (en) 2001-05-08
FI932561A (fi) 1993-06-04
WO1992010755A1 (en) 1992-06-25
FI932561A0 (fi) 1993-06-04
JP2003174871A (ja) 2003-06-24
KR930703610A (ko) 1993-11-30
ATE170630T1 (de) 1998-09-15
AU9052891A (en) 1992-07-08
KR100237968B1 (ko) 2000-01-15
CA2331936C (en) 2007-07-31
EP0561907A1 (de) 1993-09-29
JP3355186B2 (ja) 2002-12-09
EP0561907B1 (de) 1998-09-02
DE69130113T2 (de) 1999-05-12
JP3450840B2 (ja) 2003-09-29
DK0561907T3 (da) 1999-05-31
BR9107206A (pt) 1993-11-03
CA2095852A1 (en) 1992-06-06

Similar Documents

Publication Publication Date Title
DE69130113D1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
ATE68826T1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE69316405D1 (de) Verfahren zur fermentativen Herstellung von Aminosäuren
DE69406158D1 (de) Verfahren zur Herstellung von Olefinen mit endständigen Doppelbindungen
DE68919246D1 (de) Verfahren zur Herstellung von Aminosäuren.
DE69129899D1 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
DE69220113D1 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
DE59100547D1 (de) Verfahren zur Herstellung von linearen Polyamiden.
DE69430975D1 (de) Verfahren zur Herstellung von Proteinen
ATE227307T1 (de) Verfahren zur herstellung modifizierten proteine
DE68910771D1 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
DE68912734D1 (de) Verfahren zur Herstellung von Tetrafluoräthylen.
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
DE59007330D1 (de) Verfahren zur Herstellung von symmetrischen Diarylacetylenen.
DE68926922D1 (de) Verfahren zur Herstellung von L-alpha-Aminosäuren
DE3785119D1 (de) Verfahren zur herstellung von aminosaeuren.
AT384032B (de) Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
DE69530176T2 (de) Verfahren zur Herstellung von Protein
DE69431097D1 (de) Verfahren zur Herstellung von humanem Serumalbumin
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
DE3884261D1 (de) Verfahren zur Herstellung von Fremdproteinen in Streptomyceten.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: NOVOZYMES A/S, BAGSVAERD, DK

8331 Complete revocation